AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 301 min read$ABBV

AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion; Adjusted EPS Reaches $3.82

AbbVie reported Q3 2026 revenue of $17.4B, up 10.3% YoY, with adjusted EPS of $3.82. The company raised its full-year adjusted EPS guidance to $13.95–$13.99 and announced a 5.2% dividend increase. Key growth drivers included Skyrizi, Rinvoq, and neuroscience portfolio products. AbbVie completed the acquisition of Apogee Therapeutics and received FDA approvals for Skyrizi and Juvmo.

Original reporting
tradingview.com
Published Oct 30, 2026, 11:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 12:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion; Adjusted EPS Reaches $3.82 — source image
Source · tradingview.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The earnings beat and guidance raise are likely to drive short‑term upside, while long‑term performance will depend on Humira trajectory.

02

Market read

Material earnings news for a major pharma company, with immediate price impact potential.

03

What to watch

Potential headwinds from Humira sales decline and upcoming competition.

Relevance 9/10Novelty 9/10Timing: after market close

Background

AbbVie’s Q3 earnings release includes revenue growth, EPS beat, guidance raise, and dividend increase.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie reported Q3 2026 revenue of $17.404B, raised full-year adjusted EPS guidance to $13.95‑$13.99 and announced a 5.2% dividend increase.

Expected impact

upward pressure as market prices in higher earnings and dividend increase

Evidence & confidence

Strong revenue growth, EPS beat, and higher guidance are material positive catalysts for a large‑cap pharma.

Market effects

Sector

Positive for the broader pharma sector as earnings beat may lift peers.

Regional

U.S. market may see modest uplift in healthcare indices.

Global

Limited to investors tracking large‑cap biotech/pharma stocks.

Counterpoint

What could challenge this read

If guidance falls short of analyst expectations, the stock could face a pullback.

Key entities

  • Company
    AbbVie

    Large‑cap biopharma reporting Q3 results.

Read at source← All news

StoryAbbVie reports Q3 2026 results, raises FY‑2026 adjusted EPS guidance and dividend

Also covered by

6 outlets

Related articles

OCT 30
$ABBVHighAI 9/10

AbbVie (ABBV) Q3 2026 Earnings Call Transcript

AbbVie (ABBV) raised its full-year revenue guidance by $200M, citing strong performance across its portfolio, including Skyrizi, Rinvoq, and Venclexta. The company also increased its quarterly dividend by 5.2%. Key developments include the acquisition of Apogee Therapeutics, FDA approvals for Skyrizi subcu induction in Crohn's, and Juvmo in Parkinson's. AbbVie expects peak sales of over $5B for its Parkinson's therapies and submitted an application for etentamig in multiple myeloma.

finance.yahoo.com3 min
OCT 30
$ABBVMedAI 8/10

Michael Burns: New Clinical Data for ABBV-400 in Metastatic Colorectal Cancer

Pfizer's Michael Burns shared new clinical data on ABBV-400 (telisotuzumab adizutecan) in metastatic colorectal cancer. The randomized Phase 1 study, published in Annals of Oncology, evaluated the novel c-Met-directed antibody-drug conjugate combined with anti-VEGF therapy. The study explored efficacy and tolerability in heavily pretreated patients, with Phase 3 trials ongoing.

oncodaily.com1 min